BCL2 and cancer: Preclinical studies showed that SCLC cell lines are among the most sensitive tumour types to ABT-737 and ABT-263 (refs 10, 11, 24, 25), suggesting that targeting the BCL-2 family proteins may be a paradigm shifting therapeutic strategy for this cancer.